← Back to Search

Radiation Therapy

Stereotactic body radiotherapy for Lung Cancer

N/A

Waitlist Available

Led By Matthew Spraker, M.D., Ph.D.

Research Sponsored by Washington University School of Medicine

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up at 6 months

Awards & highlights

Study Summary

This trial is testing a new, more effective way to give palliative radiotherapy to patients with large tumors.

Eligible Conditions

Lung Cancer
Sarcoma
Abdominal Cancer
Pelvic Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ at 6 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~at 6 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and at 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of Participants With Treatment-related, Non-hematologic Grade ≥ 3 Toxicity

Rate of Local Control

Secondary outcome measures

Patient Reported Pain as Measured by Numeric Pain Scale

Patient Reported Toxicity as Measured by PRO-CTCAE Assessment

Quality of Life as Measured by PROMIS Anxiety Assessment

+3 more

Side effects data

From 2018 Phase 4 trial • 19 Patients • NCT01344356

100%

Dizziness

100%

Cranial Nerve Neuropathy

100%

Fatigue

100%

Alopecia

100%

Mucositis

100%

80%

60%

40%

20%

Study treatment Arm

Benign Tumors

Malignant Tumors

Trial Design

1Treatment groups

Experimental Treatment

Group I: SBRTExperimental Treatment2 Interventions

5-fraction Lattice SBRT delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Stereotactic body radiotherapy

2014

Completed Phase 4

~370

Research blood draw

2022

Completed Phase 2

~240

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Washington University School of MedicineLead Sponsor

1,935 Previous Clinical Trials

2,299,740 Total Patients Enrolled

Goldman Sachs Foundation (Emerson Collective)UNKNOWN

Matthew Spraker, M.D., Ph.D.Principal InvestigatorWashington University School of Medicine

3 Previous Clinical Trials

30 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there still opportunities to participate in this research endeavor?

"According to the clinicaltrials.gov website, this specific medical trial is not actively looking for participants at present time. It was initially posted on September 22nd 2020 and last amended October 17th 2022 but there are currently 484 other research initiatives accepting new patients."

Answered by AI

Recent research and studies

Advances in Radiation OncologyJournal

Spatially Fractionated Stereotactic Body Radiation Therapy (lattice) for Large Tumors

Duriseti, Sai, James Kavanaugh, Sreekrishna Goddu, Alex Price, Nels Knutson, Francisco Reynoso, Jeff Michalski, Sasa Mutic, Clifford Robinson, and Matthew B. Spraker. 2021. “Spatially Fractionated Stereotactic Body Radiation Therapy (lattice) for Large Tumors”. Advances in Radiation Oncology. Elsevier BV. doi:10.1016/j.adro.2020.100639.

clinicaltrials.govStudy

Palliative Lattice Stereotactic Body Radiotherapy (SBRT) for Patients With Sarcoma, Thoracic, Abdominal, and Pelvic Cancers

2020. "Palliative Lattice Stereotactic Body Radiotherapy (SBRT) for Patients With Sarcoma, Thoracic, Abdominal, and Pelvic Cancers". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04553471.